Researchers at Niigata University identified a novel calcium-independent mechanism driving nephrotic syndrome through direct stimulation of Ephrin-B1, News-Medical reported.
The glomerulus acts as the primary filtration unit of the kidney, utilizing capillary walls to prevent plasma proteins from leaking into urine. Proteinuria arises when this filtration barrier fails, aggravating kidney function and raising cardiovascular and cerebrovascular disease risks.
Podocytes sit on the outer layer of the glomerular capillary wall with specialized foot processes connected by slit diaphragms. While autoantibodies against nephrin can trigger slit diaphragm damage, researchers previously lacked a clear understanding of many nephrotic syndrome pathways.
The research team focused on Ephrin-B1, a protein that binds to nephrin, and demonstrated that direct stimulation of Ephrin-B1 causes podocyte injury. This stimulation triggers phosphorylation in both Ephrin-B1 and nephrin independently of calcium influx, distinguishing it from anti-nephrin antibody pathways that require TRPC6-mediated calcium entry.
Downstream Signaling Cascades
Phosphorylated Ephrin-B1 separates from nephrin and another binding protein named Par6. Once released, Par6 interacts with the signaling protein Cdc42 and increases its activity.
Elevated Cdc42 activity boosts calcineurin function, which alters the transcription factor Snail and reduces the mRNA expression of nephrin and Ephrin-B1. Simultaneously, active Cdc42 stimulates Stat3 independently of calcineurin, driving the expression of claudin-1 as a marker of podocyte dedifferentiation.
Laboratory tests showed that a Cdc42 inhibitor successfully stopped both the downregulation of nephrin and Ephrin-B1 and the rise of claudin-1. Conversely, a calcineurin inhibitor and an angiotensin II type 1 receptor blocker prevented the loss of nephrin and Ephrin-B1 but failed to block claudin-1 induction.
Potential Therapeutic Strategies
Targeting Cdc42 may offer a more effective approach for restoring podocyte homeostasis. The study highlights Ephrin-B1 signaling as a distinct therapeutic target for treating proteinuric kidney diseases.
“Targeting Cdc42 may represent a more effective therapeutic strategy for restoring podocyte homeostasis,” the researchers said in The American Journal of Pathology.
Study Questions and Answers
What role do podocytes play in kidney filtration?
Podocytes are specialized cells located on the outer layer of the glomerular capillary wall. Their foot processes form slit diaphragms that act as the final barrier to prevent plasma proteins from entering the urine.
How does Ephrin-B1 differ from anti-nephrin antibodies in causing injury?
Ephrin-B1 stimulation induces podocyte injury independently of calcium influx through downstream Cdc42 and calcineurin activation. In contrast, injury caused by anti-nephrin antibodies requires TRPC6-mediated calcium influx.
Which inhibitors blocked the cellular changes in the study?
A Cdc42 inhibitor prevented both the downregulation of nephrin and Ephrin-B1 expression and the induction of claudin-1. Meanwhile, calcineurin inhibitors and angiotensin II type 1 receptor blockers only prevented the loss of nephrin and Ephrin-B1.
Worth a look